



***Innovative back microsurgery***

**Press release**

## **VEXIM joins the EnterNext<sup>®</sup> PEA-PME 150 index**

**Toulouse, November 17, 2014 - VEXIM (FR0011072602 - ALVXM / PEA-PME eligible)**, a medical device company specializing in the minimally-invasive treatment of vertebral fractures, today announced it has been chosen to be included in the new EnterNext<sup>®</sup> PEA-PME 150 index.

**Vincent Gardès, CEO of VEXIM, comments:** *“This new index provides investors with a benchmark regarding the stock-market performances of listed French SMEs with the largest free float market capitalization, and we are delighted to be one of those companies. This will enable us to further increase our visibility within the stock-market community. Indeed, it is thanks to the support of institutional and individual investors that we have been able to deploy an efficient European sales network and multiply our sales fivefold in just two years to €6.1 million in 2013. We are thus getting ever closer to our aim of becoming a leader in the treatment of vertebral fractures.”*

### **About EnterNext<sup>®</sup> PEA-PME 150 Index**

The EnterNext<sup>®</sup> PEA-PME 150 consists of 150 French companies covered by EnterNext and listed on Euronext and Alternext markets in Paris; all count among the 80% most liquid shares eligible for PEA-PME accounts. Shares are ranked by the size of their float; weighting of each is capped at 2.5%, with a 20% limit per sector. The index will be revised once a year and its weighting will be reviewed every quarter.

This new index is a response to industry demand for new benchmarks for midcaps. The wide range of sectors it covers gives investors a good overview of France’s most liquid small and mid-caps.

### **About VEXIM, the innovative back microsurgery specialist**

Based in Balma, near Toulouse (France), VEXIM is a medical device company created in 2006. The Company has specialized in the creation and marketing of mini-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholders, Truffle Capital and Banexi Venture, and from Bpifrance public subsidies, VEXIM has designed and developed the SpineJack<sup>®</sup>, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 58 staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland and the United Kingdom, as well as distributors notably in Argentina, India, Taiwan, Belgium, South Africa, Colombia, Panama, Venezuela, Chile, and Ecuador and in the following countries where the product is currently being registered: Mexico, Brazil and Peru. VEXIM has been listed on Alternext Paris since May 2012.

For further information, please go to [www.vexim.com](http://www.vexim.com)

## SpineJack®<sup>1</sup> implant for treating Vertebral Compression Fractures

An important advantage of SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column's optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Specialized instruments and guided by X-ray allow the implants into the vertebra to be carried out by mini-invasive surgery in approximately 30 minutes enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of three titanium implants with three different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies. SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection until 2029. SpineJack® is an investigational device in the United States and is not available for U.S. sale.

## Contacts

### VEXIM

**Vincent Gardès**

CEO

Tel: +33 5 61 48 48 38

[shareholders@vexim.com](mailto:shareholders@vexim.com)

### NewCap

Investor Relations /

Strategic

Communications

**Dusan Oresansky /**

**Emmanuel Huynh**

Tel: +33 1 44 71 94 92

[vexim@newcap.fr](mailto:vexim@newcap.fr)

### Alize RP

Press Relations

**Caroline Carmagnol /**

**Sophie Colin**

[vexim@alizerp.com](mailto:vexim@alizerp.com)

Tel: +33 1 70 22 53 93 /

+33 6 64 18 99 59

### LifeSci Advisors LLC

Investor Relations

**Michael Wood**

[www.lifesciadvisors.com](http://www.lifesciadvisors.com)

+1 646 597 6983



- **Name:** VEXIM
- **ISIN code:** FR0011072602
- **Ticker:** ALVXM



---

<sup>1</sup> This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use.